News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lee's Pharmaceutical Gains China Rights To Labor-Inducing Drug


2/20/2014 3:23:10 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

February 20, 2014 -- Lee’s Pharma has in-licensed China Rights to tafoxiparin, a clinical-stage product from Dilafor AB of Sweden. Tafoxiparin is a heparin derivative that has completed a Phase II trial as a treatment to induce labor. Lee’s will be responsible for conducting Phase II and III trials of the drug in China. Specific financial terms of the deal were not disclosed. More details....

Stock Symbol: (HK: 950)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES